Kairos Pharma, LTD.
KAPA · XNYSCIK 1962011fmd_0QNF9ZYRN0N537YZD1KP6EXFC7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Jun 30, 2026, 12 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 0 | 0 | 2 |
| Total operating expenses | 2 | 2 | 6 |
| Operating income | (2) | (2) | (6) |
| Interest expense | 0 | 0 | – |
| Other non-operating income (expense) | (0) | (0) | 0 |
| Net income | (2) | (3) | (5) |